Rodent models and contemporary molecular techniques: Notable feats yet incomplete explanations of Parkinson's disease pathogenesis

Molecular Neurobiology

Volumn 46, Issue 2, 2012, Pages 495-512

  Yadav, Sharawan ^a   Dixit, Anubhuti ^a   Agrawal, Sonal ^a   Singh, Ashish ^a   Srivastava, Garima ^a   Singh, Anand Kumar ^a   Srivastava, Pramod Kumar ^b   Prakash, Om ^b   Singh, Mahendra Pratap ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

Genomics; Parkinson's disease; Proteomics; RNA interference; Rodent models; Transcriptomics

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; MANEB; METAL; OXIDOPAMINE; PARAQUAT; PESTICIDE; ROTENONE; TOXIN;

ARTICLE; DISEASE MODEL; GENETIC MODEL; MEDICAL LITERATURE; MOLECULAR BIOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEOMICS; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SUBSTANTIA NIGRA;

EID: 84868147021     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-012-8291-8     Document Type: Article

References (171)

1. Parkinson J (2002) An essay on the shaking palsy 1817. J Neuropsychiatry Clin Neurosci 14:223-236
2. Goetz CG (1986) Charcot on Parkinson's disease. Mov Disord 1:27-32
3. Singh MP, Patel S, Dikshit M, Gupta YK (2006) Contribution of genomics and proteomics in understanding the role of modifying factors in Parkinson's disease. Indian J Biochem Biophys 43:69-81 (Pubitemid 44475398)
4. Miller RL, James-Kracke M, Sun GY, Sun AY (2009) Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 34:55-65
5. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J (2011) Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 26:S1-S58
6. Klockgether T (2004) Parkinson's disease: clinical aspects. Cell Tissue Res 318:115-120 (Pubitemid 39362632)
7. Morgan JC, Mehta SH, Sethi KD (2010) Biomarkers in Parkinson's disease. Curr Neurol Neurosci Rep 10:423-430
8. Ebin J (1951) Surgical treatment of Parkinsonism: indications and results. Bull N Y Acad Med 27:653-678
9. Cicchetti F, Drouin-Ouellet J, Gross RE (2009) Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models? Trends Pharmacol Sci 30:475-483
10. Singhal NK, Srivastava G, Agrawal S, Jain SK, Singh MP (2012) Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation? Mol Neurobiol 45:186-199
11. Kumar A, Ahmad I, Shukla S, Singh BK, Patel DK, Pandey HP, Singh C (2010) Effect of zinc and paraquat co-exposure on neurodegeneration: modulation of oxidative stress and expression of metallothioneins, toxicant responsive and transporter genes in rats. Free Radic Res 44:950-965
12. Khalid M, Aoun RA, Mathews TA (2011) Altered striatal dopamine release following a sub-acute exposure to manganese. J Neurosci Methods 202:182-191
13. Singh AK, Tiwari MN, Upadhyay G, Patel DK, Singh D, Prakash O, Singh MP (2012) Long-term exposure to cypermethrin induces nigrostriatal dopaminergic neurodegeneration in adult rats: postnatal exposure enhances the susceptibility during adulthood. Neurobiol Aging 33:404-415
14. Betarbet R, Sherer TB, Greenamyre JT (2002) Animal models of Parkinson's disease. Bioessays 24:308-318 (Pubitemid 34305686)
15. Thiruchelvam M, Brockel BJ, Richfield EK, Baggs RB, Cory-Slechta DA (2000) Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Res 873:225-234 (Pubitemid 30619046)
16. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980 (Pubitemid 13189531)
17. Patel S, Singh V, Kumar A, Gupta YK, Singh MP (2006) Status of antioxidant defense system and expression of toxicant responsive genes instriatumofmaneb and paraquat-inducedParkinson'sdisease phenotype in mouse: mechanism of neurodegeneration. Brain Res 108:9-18
18. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, Richardson RJ (1999) Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 20:239-247
19. Singh AK, Tiwari MN, Dixit A, Upadhyay G, Patel DK, Singh D, Prakash O, Singh MP (2011) Nigrostriatal proteomics of cypermethrin-induced dopaminergic neurodegeneration: microglial activation dependent and independent regulations. Toxicol Sci 122:526-538
20. Srivastava G, Dixit A, Yadav S, Patel DK, Prakash O, Singh MP (2012) Resveratrol potentiates cytochrome P450 2d22-mediated neuroprotection in maneb-and paraquat-induced parkinsonism in the mouse. Free Radic Biol Med 52:1294-1306
21. Srivastava G, Singh K, Tiwari MN, Singh MP (2010) Proteomics in Parkinson's disease: current trends, translational snags and future possibilities. Expert Rev Proteomics 7:127-139
22. Srivastava G, Dixit A, Prakash O, Singh MP (2011) Tiny noncoding RNAs in Parkinson's disease: Implications, expectations and hypes. Neurochem Int 59:759-769
23. Klein C, Schlossmacher MG (2007) Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 69:2093-2104 (Pubitemid 350175712)
24. Gao HM, Hong JS (2011) Gene-environment interactions: key to unravelingthemysteryofParkinson'sdisease.ProgNeurobiol94:1-19
25. Uversky VN (2004) Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 318:225-241 (Pubitemid 39362642)
26. Ginsberg SD, Mirnics K (2006) Functional genomic methodologies. Prog Brain Res 158:15-40
27. Shilling PD, Kelsoe JR (2002) Functional genomics approaches to understanding brain disorders. Pharmacogenomics 3:31-45 (Pubitemid 34285237)
28. Vargas RH, Ornelas LF, González IL, Escovar JR, Zurita M, Reynaud E (2011) Synphilin suppresses α-synuclein neurotoxicity in a Parkinson's disease Drosophila model. Genesis 49:392-402
29. Ramsden DB, Parsons RB, Ho SL, Waring RH (2001) The aetiology of idiopathic Parkinson's disease. Mol Pathol 54:369-380 (Pubitemid 34025251)
30. Migliore L, Coppede F (2009) Environmental-induced oxidative stress in neurodegenerative disorders and aging. Mutat Res 674:73-84
31. Wood-Kaczmar A, Gandhi S, Wood NW (2006) Understanding the molecular causes of Parkinson's disease. Trends Mol Med 12:521-528 (Pubitemid 44633809)
32. Bove J, Prou D, Perier C, Przedborski S (2005) Toxin-induced models of Parkinson's disease. NeuroRx 2:484-494 (Pubitemid 41444882)
33. Ascherio A, Chen H,WeisskopfMG, O'Reilly E, McCulloughML, Calle EE, Schwarzschild MA, Thun MJ (2006) Pesticide exposure and risk for Parkinson's disease. Ann Neurol 60:197-203 (Pubitemid 44182394)
34. He Y, Appel S, Le W (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909:187-193 (Pubitemid 32710132)
35. Silva RM, Ries V, Oo TF,YaryginaO, Jackson-LewisV, Ryu EJ, Lu PD, Marciniak SJ, Ron D, Przedborski S, Kholodilov N, Greene LA, Burke RE (2005) CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J Neurochem 95:974-986 (Pubitemid 41713483)
36. Reyes S, Mitrofanis J (2008) Patterns of FOS expression in the spinal cord and periaqueductal grey matter of 6OHDA-lesioned rats. Int J Neurosci 118:1053-1079 (Pubitemid 351896782)
37. Latchoumycandane C, Anantharam V, Jin H, Kanthasamy A, Kanthasamy A (2011) Dopaminergic neurotoxicant (2011) 6-OHDA induces oxidative damage through proteolytic activation of PKCδ in cell culture and animal models of Parkinson's disease. Toxicol Appl Pharmacol 256:314-323
38. Bernstein AI, Garrison SP, Zambetti GP, O'Malley KL (2011) 6-OHDA generated ROS induces DNA damage and p53-and PUMA-dependent cell death. Mol Neurodegener 6:2
39. Proft J, Faraji J, Robbins JC, Zucchi FC, Zhao X, Metz GA, Braun JE (2011) Identification of bilateral changes in TID1 expression in the 6-OHDA rat model of Parkinson's disease. PLoS One 6:e26045
40. Przedborski S, Vila M (2003) The 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 991:189-198 (Pubitemid 36793814)
41. Ross CA, Smith WW (2007) Gene-environment interactions in Parkinson's disease. Parkinsonism Relat Disord 13:S309-S315 (Pubitemid 351215260)
42. Cui M, Aras R, Christian WV, Rappold PM, Hatwar M, Panza J, Jackson-Lewis V, Javitch JA, Ballatori N, Przedborski S, Tieu K (2009) The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A 106:8043-8048
43. Karunakaran S, Saeed U, Mishra M, Valli RK, Joshi SD, Meka DP, Seth P, Ravindranath V (2008) Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. J Neurosci 28:12500-12509
44. Castro-Caldas M, Carvalho AN, Rodrigues E, Henderson C, Wolf CR, GamaMJ (2012) Glutathione S-transferase pi mediatesMPTPinduced c-Jun N-terminal kinase activation in the nigrostriatal pathway. Mol Neurobiol. doi:10.1007/s12035-012- 8266-9
45. Zawada WM, Banninger GP, Thornton J, Marriott B, Cantu D, Rachubinski AL, Das M, Griffin WS, Jones SM (2011) Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP +) treated dopaminergic neurons occurs as an NADPH oxidasedependent two-wave cascade. J Neuroinflammation 8:129
46. Durgadoss L, Nidadavolu P, Valli RK, Saeed U, Mishra M, Seth P, Ravindranath V (2012) Redox modification of Akt mediated by the dopaminergic neurotoxin MPTP, in mouse midbrain, leads to down-regulation of pAkt. FASEB J 26:1473-1483
47. Jeong HJ, Kim DW, Woo SJ, Kim HR, Kim SM, Jo HS, Park M, Kim DS, Kwon OS, Hwang IK, Han KH, Park J, Eum WS, Choi SY (2012) Transduced Tat-DJ-1 protein protects against oxidative stress-induced SH-SY5Y cell death and Parkinson disease in a mouse model. Mol Cells. doi:10.1007/s10059-012-2255-8
48. Martin HL, Mounsey RB, Mustafa S, Sathe K, Teismann P (2012) Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease. Exp Neurol 235:528-538
49. Park HK, Cho AR, Lee SC, Ban JY (2012) MPTP-induced model of Parkinson's disease in heat shock protein 70.1 knockout mice. Mol Med Report 5:1465-1468
50. Domenger D, Dea D, Theroux L, Moquin L, Gratton A, Poirier J (2012) The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain. Exp Neurol 233:513-522
51. Airavaara M, Harvey BK, Voutilainen MH, Shen H, Chou J, Lindholm P, Lindahl M, Tuominen RK, Saarma M, Wang Y, Hoffer B (2011) CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplant. doi:10.3727/096368911X600948
52. Bezard E, Przedborski S (2011) A tale on animal models of Parkinson's disease. Mov Disord 26:993-1002
53. LoPachin RM, Gavin T (2008) Response to "Paraquat: the red herring of Parkinson's disease research". Toxicol Sci 103:219-221 (Pubitemid 351524494)
54. Shimizu K, Ohtaki K, Matsubara K, Aoyama K, Uezono T, Saito O, Suno M, Ogawa K, Hayase N, Kimura K, Shiono H (2001) Carrier-mediated processes in blood-brain barrier penetration and neural uptake of paraquat. Brain Res 906:135-142 (Pubitemid 32595547)
55. Feng LR, Maguire-Zeiss KA (2011) Dopamine and paraquat enhance α-synuclein-induced alterations in membrane conductance. Neurotox Res 20:387-401
56. Miller RL, Sun GY, Sun AY (2007) Cytotoxicity of paraquat in microglial cells: involvement of PKCdelta-and ERK1/2-dependent NADPH oxidase. Brain Res 1167:129-139 (Pubitemid 47302435)
57. Huang CL, Lee YC, Yang YC, Kuo TY, Huang NK (2012) Minocycline prevents paraquat-induced cell death through attenuating endoplasmic reticulum stress and mitochondrial dysfunction. Toxicol Lett 209:203-210
58. Rappold PM, Cui M, Chesser AS, Tibbett J, Grima JC, Duan L, Sen N, Javitch JA, Tieu K (2011) Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. Proc Natl Acad Sci U S A 108:20766-20771
59. Fei Q, Ethell DW (2008) Maneb potentiates paraquat neurotoxicity by inducing key Bcl-2 family members. J Neurochem 105:2091-2097 (Pubitemid 351782244)
60. Litteljohn D, Nelson E, Bethune C, Hayley S (2011) The effects of paraquat on regional brain neurotransmitter activity, hippocampal BDNF and behavioural function in female mice. Neurosci Lett 502:186-191
61. Kachroo A, Irizarry MC, Schwarzschild MA (2010) Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp Neurol 223:657-661
62. Wang A, Costello S, Cockburn M, Zhang X, Bronstein J, Ritz B (2011) Parkinson's disease risk from ambient exposure to pesticides. Eur J Epidemiol 26:547-555
63. Kang H, Han BS, Kim SJ, Oh YJ (2012) Mechanisms to prevent caspase activation in rotenone-induced dopaminergic neurodegeneration: role of ATP depletion and procaspase-9 degradation. Apoptosis 17:449-462
64. Shin EJ, Kim EM, Lee JA, Rhim H, Hwang O (2012) Matrix metalloproteinase-3 is activated by HtrA2/Omi in dopaminergic cells: relevance to Parkinson's disease. Neurochem Int 60:249-256
65. Meredith GE, Sonsalla PK, ChesseletMF (2008) Animal models of Parkinson's disease progression. Acta Neuropathol 115:385-398
66. Ritz BR, Manthripragada AD, Costello S, Lincoln SJ, Farrer MJ, Cockburn M, Bronstein J (2009) Dopamine transporter genetic variants and pesticides in Parkinson's disease. Environ Health Perspect 117:964-969
67. Moretto A, Colosio C (2011) Biochemical and toxicological evidence of neurological effects of pesticides: the example of Parkinson's disease. Neurotoxicology 32:383-391
68. Singh AK, Tiwari MN, Prakash O, Singh MP (2012) A current review of cypermethrin-induced neurotoxicity and nigrostriatal dopaminergic neurodegeneration. Curr Neuropharmacol 10:64-71
69. Sharma H, Zhang P, Barber DS, Liu B (2010) Organochlorine pesticides dieldrin and lindane induce cooperative toxicity in dopaminergic neurons: role of oxidative stress. Neurotoxicology 31:215-222
70. Cass W (1996) GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine. J Neurosci 16:8132-8139 (Pubitemid 26405073)
71. Howard CD, Keefe KA, Garris PA, Daberkow DP (2011) Methamphetamine neurotoxicity decreases phasic, but not tonic, dopaminergic signaling in the rat striatum. J Neurochem 118:668-676
72. Morrow BA, Roth RH, Redmond DE, Elsworth JD (2011) Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson's disease. Neuroscience 189:277-285
73. Callaghan RC, Cunningham JK, Sykes J, Kish SJ (2012) Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend 120:35-40
74. Kousik SM, Graves SM, Napier TC, Zhao C, Carvey PM (2011) Methamphetamine-induced vascular changes lead to striatal hypoxia and dopamine reduction. Neuroreport 22:923-928
75. Brar S, Henderson D, Schenck J, Zimmerman EA (2009) Iron accumulation in the substantia nigra of patients with Alzheimer disease and parkinsonism. Arch Neurol 66:371-374
76. Jomova K, Valko M (2011) Advances in metal-induced oxidative stress and human disease. Toxicology 283:65-87
77. Kienzl E, Puchinger L, Jellinger K, Linert W, Stachelberger H, Jameson RF (1995) The role of transition metals in the pathogenesis of Parkinson's disease. J Neurol Sci 134:69-78
78. Kumar A, Singh BK, Ahmad I, Shukla S, Patel DK, Srivastava G, Kumar V, Pandey HP, Singh C (2012) Involvement of NADPH oxidase and glutathione in zinc-induced dopaminergic neurodegeneration in rats: similarity with paraquat neurotoxicity. Brain Res 1438:48-64
79. Gash DM, Rutland K, Hudson NL, Sullivan PG, Bing G, Cass WA, Pandya JD, Liu M, Choi DY, Hunter RL, Gerhardt GA, Smith CD, Slevin JT, Prince TS (2008) Trichloroethylene: parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol 63:184-192 (Pubitemid 351355297)
80. Holtcamp W (2012) The emerging science of BMAA: do cyanobacteria contribute to neurodegenerative disease? Environ Health Perspect 120:A110-A116
81. Lannuzel A, Michel PP, Höglinger GU, Champy P, Jousset A, Medja F, Lombès A, Darios F, Gleye C, Laurens A, Hocquemiller R, Hirsch EC, Ruberg M (2003) The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism. Neuroscience 121:287-296 (Pubitemid 37176917)
82. Storch A, Ott S, Hwang YI, Ortmann R, Hein A, Frenzel S, Matsubara K, Ohta S, Wolf HU, Schwarz J (2002) Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter. Biochem Pharmacol 63:909-920 (Pubitemid 34243004)
83. Ohta S, Tachikawa O, Makino Y, Tasaki Y, Hirobe M (1990) Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ) a possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizer. Life Sci 46:599-605 (Pubitemid 20070639)
84. Mohajjel Nayebi AA, Sheidaei H (2010) Buspirone improves haloperidol-induced Parkinson disease in mice through 5-HT (1A) recaptors. Daru 18:41-45
85. McNaught KS, Perl DP, Brownell AL, Olanow CW (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56:149-162 (Pubitemid 38857373)
86. Panneton WM, Kumar VB, Gan Q, Burke WJ, Galvin JE (2010) The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS One 5: e15251
87. Gasser T (2007) Update on the genetics of Parkinson's disease. Mov Disord 17:S343-S350 (Pubitemid 350134187)
88. Bekris LM, Mata IF, Zabetian CP (2010) The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 23:228-242
89. Fujioka S, Wszolek ZK (2012) Update on genetics of parkinsonism. Neurodegener Dis 10:257-260
90. Terzioglu M, Galter D (2008) Parkinson's disease: genetic versus toxin-induced rodent models. FEBS J 275:1384-1391 (Pubitemid 351388790)
91. Hisahara S, Shimohama S (2010) Toxin-induced and genetic animal models of Parkinson's disease. Parkinsons Dis 2011:951709
92. Manning-Bog AB, Langston JW (2007) Model fusion, the next phase in developing animal models for Parkinson's disease. Neurotox Res 11:219-240
93. Boger HA, Granholm AC, McGinty JF, Middaugh LD (2010) A dual-hit animal model for age-related Parkinsonism. Prog Neurobiol 90:217-229
94. Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS (2011) Neuroinflammation and α-synuclein dysfunction potentiate each other, drivingchronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ Health Perspect 119:807-814
95. Jakowec MW, Petzinger GM (2004) 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis onmice and nonhuman primates. CompMed 54:497-513 (Pubitemid 39557443)
96. Zhu XR, Maskri L, Herold C, Bader V, Stichel CC, Güntürkün O, Lübbert H (2007) Non-motor behavioural impairments in parkindeficient mice. Eur J Neurosci 26:1902-1911 (Pubitemid 47493196)
97. Emborg ME (2007) Nonhuman primate models of Parkinson's disease. ILAR J 48:339-355 (Pubitemid 350194367)
98. Duty S, Jenner P (2011) Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164:1357-1391
99. Pienaar IS, Götz J, Feany MB (2010) Parkinson's disease: insights from non-traditional model organisms. Prog Neurobiol 92:558-571
100. Antony PM, Diederich NJ, Balling R (2011) Parkinson's disease mouse models in translational research. Mamm Genome 22:401-419
101. Chesselet MF, Richter F (2011) Modelling of Parkinson's disease in mice. Lancet Neurol 10:1108-1118
102. Potashkin JA, Blume SR, Runkle NK (2010) Limitations of animal models of Parkinson's disease. Parkinsons Dis 2011:658083
103. Mellick GD, Silburn PA, Sutherland GT, Siebert GA (2010) Exploiting the potential of molecular profiling in Parkinson's disease: current practice and future probabilities. Expert Rev Mol Diagn 10:1035-1050
104. Miller RM, Federoff HJ (2006) Microarrays in Parkinson's disease: a systematic approach. NeuroRx 3:319-326 (Pubitemid 43946714)
105. Chang XL, Mao XY, Li HH, Zhang JH, Li NN, Burgunder JM, Peng R, Tan EK (2011) Association of GWAS loci with PD in China. Am J Med Genet B Neuropsychiatr Genet 156B:334-339
106. Biernacka JM, Armasu SM, Cunningham JM, Eric Ahlskog J, Chung SJ, Maraganore DM (2011) Do interactions between SNCA, MAPT, and LRRK2 genes contribute to Parkinson's disease susceptibility? Parkinsonism Relat Disord 17:730-736
107. Chung SJ, Armasu SM, Biernacka JM, Lesnick TG, Rider DN, Lincoln SJ, Ortolaza AI, Farrer MJ, Cunningham JM, Rocca WA, Maraganore DM (2011) Common variants in PARK loci and related genes and Parkinson's disease. Mov Disord 26:280-288
108. Autere J, Moilanen JS, Finnila S, Soininen H, Mannermaa A, Hartikainen P, Hallikainen M, Majamaa K (2004) Mitochondrial DNA polymorphisms as risk factors for Parkinson's disease and Parkinson's disease dementia. Hum Genet 115:29-35 (Pubitemid 38787215)
109. Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, Andersen SL, Stephens RM, Benes FM, Sonntag KC (2009) Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 132:1795-1809
110. Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, Li J, Ravid R, Roggendorf W, Riederer P, Youdim MB (2004) Gene expression profiling of parkinsonian substantia nigra pars compacta alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111:1543-1573 (Pubitemid 40068786)
111. Patel S, SinghK, Singh S, SinghMP(2008)Gene expression profiles of mouse striatum in control and maneb+paraquat-induced Parkinson'sdiseasephenotype: validationof differentiallyexpressedenergy metabolizing transcripts.Mol Biotechnol 40:59-68
112. Duke DC, Moran LB, Kalaitzakis ME, Deprez M, Dexter DT, Pearce RK, Graeber MB (2006) Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. Neurogenetics 7:139-148 (Pubitemid 44078291)
113. Miller RM, Kiser GL, Kaysser-Kranich TM (2006) Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiol Dis 21:305-313 (Pubitemid 43099854)
114. Chin MH, Qian WJ, Wang H, Petyuk VA, Bloom JS, Sforza DM, Laćan G, Liu D, Khan AH, Cantor RM, Bigelow DJ, Melega WP, Camp DG 2nd, Smith RD, Smith DJ (2008) Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson's disease. J Proteome Res 7:666-677 (Pubitemid 351294029)
115. Cadet JL, Brannock C, Krasnova IN, Ladenheim B, McCoy MT, Chou J, Lehrmann E, Wood WH, Becker KG, Wang Y (2010) Methamphetamine-induced dopamine-independent alterations in striatal gene expression in the 6-hydroxydopamine hemiparkinsonian rats. PLoS One 5:e15643
116. Pickrell AM, Fukui H, Wang X, Pinto M, Moraes CT (2011) The striatum is highly susceptible to mitochondrial oxidative phosphorylation dysfunctions. J Neurosci 631:9895-9904
117. Grünblatt E (2012) Parkinson's disease: molecular risk factors. Parkinsonism Relat Disord 18(Suppl 1):S45-S48
118. Wernicke C, Hellmann J, Zieba B, Kuter K, Ossowska K, Frenzel M, Dencher NA, Rommelspacher H (2010) 9-Methyl-beta-carboline has restorative effects in an animal model of Parkinson's disease. Pharmacol Rep 62:35-53
119. Pattarini R, Rong Y, Qu C, Morgan JI (2008) Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum. Neuroscience 155:1174-1194
120. Chung CY, Seo H, Sonntag KC, Brooks A, Lin L, Isacson O (2005) Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 14:1709-1725 (Pubitemid 41418045)
121. Mandel S, Grunblatt E, Maor G, Youdim MB (2002) Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem Res 27:1231-1243 (Pubitemid 35316119)
122. Grunblatt E, Mandel S, Maor G, Youdim MB (2001) Gene expression analysis in N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J Neurochem 78:1-12 (Pubitemid 32622583)
123. Tomita H, Vawter MP, Walsh DM, Evans SJ, Choudary PV, Li J, Overman KM, Atz ME, Myers RM, Jones EG, Watson SJ, Akil H, BunneyWE Jr (2004) Effect of agonal and postmortem factors on gene expression profile: quality control in microarray analyses of postmortem human brain. Biol Psychiatry 55:346-352 (Pubitemid 38199983)
124. Mischak H, Apweiler R, Banks RE, Conaway M, Coon J, Dominiczak A, Ehrich JH, Fliser D, Girolami M, Hermjakob H, Hochstrasser D, Jankowski J, Julian BA, Kolch W, Massy ZA, Neusuess C, Novak J, Peter K, Rossing K, Schanstra J, Semmes OJ, Theodorescu D, Thongboonkerd V, Weissinger EM, Van Eyk JE, Yamamoto T (2007) Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin Appl 1:148-156
125. Zhang J, Keene CD, Pan C, Montine KS, Montine TJ (2008) Proteomics of human neurodegenerative diseases. J Neuropathol Exp Neurol 67:923-932
126. Pienaar IS, Daniels WM, Gotz J (2008) Neuroproteomics as a promising tool in Parkinson's disease research. J Neural Transm 115:1413-1430
127. Butler GS, Overall CM (2009) Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nat Rev Drug Discov 8:935-948
128. Farley AR, Link AJ (2009) Identification and quantification of protein posttranslational modifications. Methods Enzymol 463:725-763
129. Hwang H, Zhang J, Chung KA, Leverenz JB, Zabetian CP, Peskind ER, Jankovic J, Su Z, Hancock AM, Pan C, Montine TJ, Pan S, Nutt J, Albin R, Gearing M, Beyer RP, Shi M, Zhang J (2010) Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev 29:79-125
130. Zhang J, Goodlett DR (2004) Proteomic approach to studying Parkinson's disease. Mol Neurobiol 29:271-288 (Pubitemid 41359111)
131. Robinson PA (2010) Understanding the molecular basis of Parkinson's disease, identification of biomarkers and routes to therapy. Expert Rev Proteomics 7:565-578
132. Liu B, Shi Q, Ma S, Feng N, Li J, Wang L, Wang X (2008) Striatal 19S Rpt6 deficit is related to alpha-synuclein accumulation in MPTP-treated mice. Biochem Biophys Res Commun 376:277-282
133. Zhang X, Zhou JY, Chin MH, Schepmoes AA, Petyuk VA, Weitz KK, Petritis BO, Monroe ME, Camp DG, Wood SA, Melega WP, Bigelow DJ, Smith DJ, Qian WJ, Smith RD (2010) Regionspecific protein abundance changes in the brain of MPTPinduced Parkinson's disease mouse model. J Proteome Res 9:1496-1509
134. Jin J, Hulette C, Wang Y (2006) Proteomic identification of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol Cell Proteomics 5:1193-1204 (Pubitemid 44103391)
135. Park B, Yang J, Yun N, Choe KM, Jin BK, Oh YJ (2010) Proteomic analysis of expression and protein interactions in a 6-hydroxydopamine-induced rat brain lesion model. Neurochem Int 57:16-32
136. Lessner G, Schmitt O, Haas SJ, Mikkat S, Kreutzer M, Wree A, Glocker MO (2010) Differential proteome of the striatum from hemiparkinsonian rats displays vivid structural remodeling processes. J Proteome Res 9:4671-4687
137. Jin J, Meredith GE, Chen L, Zhou Y, Xu J, Shie FS, Lockhart P, Zhang J (2005) Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease. Brain Res Mol Brain Res 134:119-138 (Pubitemid 40403644)
138. Shi M, Caudle WM, Zhang J (2009) Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol Dis 35:157-164
139. Goldknopf IL (2008) Blood-based proteomics for personalized medicine: examples from neurodegenerative disease. Expert Rev Proteomics 5:1-8 (Pubitemid 351287735)
140. Sinha A, Srivastava N, Singh S, Singh AK, Bhushan S, Shukla R, Singh MP (2009) Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson's disease patients: a proteomic approach. Clin Chim Acta 400:14-20
141. van Dijk KD, Teunissen CE, Drukarch B, Jimenez CR, Groenewegen HJ, Berendse HW, van de Berg WD (2010) Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. Neurobiol Dis 39:229-241
142. Tribl F,MarcusK, Bringmann G,MeyerHE, GerlachM, Riederer P (2006) Proteomics of the human brain: sub-proteomes might hold the key to handle brain complexity. J Neural Transm 113:1041-1054 (Pubitemid 44079937)
143. Sinha A, Patel S, Singh MP, Shukla R (2007) Blood proteome profiling in case controls and Parkinson's disease patients in Indian population. Clin Chim Acta 380:232-234 (Pubitemid 46498055)
144. Chen HM, Lin CY, Wang V (2011) Amyloid P component as a plasma marker for Parkinson's disease identified by a proteomic approach. Clin Biochem 44:377-385
145. Waragai M, Wei J, Fujita M, Nakai M, Ho GJ, Masliah E, Akatsu H, Yamada T, Hashimoto M (2006) Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun 345:967-972 (Pubitemid 43776502)
146. Muntané G, Dalfó E, Martinez A, Ferrer I (2008) Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience 152:913-923
147. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, Li L (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 279:13256-13264 (Pubitemid 38445905)
148. Salahpour A, Medvedev IO, Beaulieu JM, Gainetdinov RR, Caron MG (2007) Local knockdown of genes in the brain using small interfering RNA: a phenotypic comparison with knockout animals. Biol Psychiatry 61:65-69 (Pubitemid 44855739)
149. Ko HS, Bailey R, Smith WW, Liu Z, Shin JH, Lee YI, Zhang YJ, Jiang H, Ross CA, Moore DJ, Patterson C, Petrucelli L, Dawson TM, Dawson VL (2009) CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci U S A 106:2897-2902
150. Ko HS, Lee Y, Shin JH, Karuppagounder SS, Gadad BS, Koleske AJ, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM (2010) Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc Natl Acad Sci U S A 107:16691-16696
151. Cai J, Donaldson A, Yang M, German MS, Enikolopov G, Iacovitti L (2009) The role of Lmx1a in the differentiation of human embryonic stem cells into midbrain dopamine neurons in culture and after transplantation into a Parkinson's disease model. Stem Cells 27:220-229
152. Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, Hannon G, Abeliovich A (2007) A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317:1220-1224
153. Nelson PT, Wang WX, Rajeev BW (2008) MicroRNAs (miRNAs) in neurodegenerative diseases. Brain Pathol 18:130-138
154. Hebert SS, De Strooper B (2009) Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci 32:199-206
155. Miñones-Moyano E, Porta S, Escaramís G, Rabionet R, Iraola S, Kagerbauer B, Espinosa-Parrilla Y, Ferrer I, Estivill X, Martí E (2011) MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 20:3067-3078
156. Greco SJ, Rameshwar P (2007) MicroRNAs regulate synthesis of the neurotransmitter substance P in human mesenchymal stem cell-derived neuronal cells. Proc Natl Acad Sci U S A 104:15484-15489 (Pubitemid 47502943)
157. Ziviani E, Tao RN, Whitworth AJ (2010) Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. Proc Natl Acad Sci USA 107:5018-5023
158. Geisler S, Holmstrom KM, Skuja D, Fiesel FC, Rothfuss OC, Kahle PJ, Springer W (2010) PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol 12:119-131
159. Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, Eklund AC, Ney PA, Ng J, McGoldrick M, Mollenhauer B, Bresnick EH, Schlossmacher MG (2008) GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A 105:10907-10912
160. Doxakis E (2010) Post-transcriptional regulation of alphasynuclein expression by mir-7 and mir-153. J Biol Chem 285:12726-12734
161. Wang G, van der Walt JM, Mayhew G, Li YJ, Zuchner S, Scott WK, Martin ER, Vance JM (2008) Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 82:283-289
162. Toda T, Momose Y, Murata M, Tamiya G, Yamamoto M, Hattori N, Inoko H (2003) Toward identification of susceptibility genes for sporadic Parkinson's disease. J Neurol 250: III40-III43
163. Galvin JE (2004) Neurodegenerative diseases: pathology and the advantage of single-cell profiling. Neurochem Res 29:1041-1051 (Pubitemid 39023480)
164. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR (2007) Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A 104:955-960 (Pubitemid 46154718)
165. Sinha A, Singh C, Parmar D, Singh MP (2007) Proteomics in clinical interventions: achievements and limitations in biomarker development. Life Sci 2080:1345-1354 (Pubitemid 46367062)
166. Patel S, Sinha A, Singh MP (2007) Identification of differentially expressed proteins in striatum of maneb-and paraquat-induced Parkinson's disease phenotype in mouse. Neurotoxicol Teratol 29:578-585 (Pubitemid 47599875)
167. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041 (Pubitemid 26383833)
168. Laterra J, Keep R, Betz LA, Goldstein GW (1999) Blood-brain barrier. In: Siegel GJ, Agranoff BW, Albers RWet al (eds) Basic neurochemistry: molecular, cellular and medical aspects, 6th edn. Lippincott-Raven, Philadelphia
169. Robbins M, Judge A, Liang L, McClintock K, Yaworski E, MacLachlan I (2007) 2′-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther 15:1663-1669 (Pubitemid 47289010)
170. Ma Z, Li J, He F, Wilson A, Pitt B, Li S (2005) Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun 330:755-759 (Pubitemid 40462151)
171. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, ManoharanM, Akira S, de Fougerolles A, Endres S, Hartmann G (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11:263-270 (Pubitemid 40460553)